25236-64-0

Basic information

• Product Name: 2,2,2-TRIFLUOROETHYL METHANESULFONATE
• Synonyms: 2,2,2-Trifluoroethyl methanesulfonate >=98.0% (GC);2,2,2-Trifluoro-ethanol 1-methanesulfonate;METHANESULFONIC ACID 2,2,2-TRIFLUOROETHYL ESTER;2,2,2-TRIFLUOROMETHYL MESYLATE;2,2,2-TRIFLUOROETHYL METHANESULFONATE;2,2,2-TRIFLUOROETHYL METHANESULPHONATE;2,2,2-Trifluoroethyl methanesulphonate 98%;2,2,2-Trifluoroethylmethanesulphonate98%
• CAS NO: 25236-64-0
• Molecular Formula: C₃H₅F₃O₃S
• Molecular Weight: 178.13
• Product Categories: Fluorinated Building Blocks;Fluorinating Reagents & Building Blocks for Fluorinated Biochemical Compounds;Synthetic Organic Chemistry;Small molecule
• Mol File: 25236-64-0.mol
• Article Data: 12

Chemical Properties

• Boiling Point: 99 °C / 35mmHg
• Flash Point: 103°C
• Appearance: /
• Density: 1.513 g/mL at 20 °C(lit.)
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: n20/D 1.367
• BRN: 1863049
• CAS DataBase Reference: 2,2,2-TRIFLUOROETHYL METHANESULFONATE(CAS DataBase Reference)
• NIST Chemistry Reference: 2,2,2-TRIFLUOROETHYL METHANESULFONATE(25236-64-0)
• EPA Substance Registry System: 2,2,2-TRIFLUOROETHYL METHANESULFONATE(25236-64-0)

Safety Data

• Hazard Codes: C
• Statements: 34-35
• Safety Statements: 26-36/37/39-45
• RIDADR: UN 3265 8/PG 3
• WGK Germany: 3
• F: 10-21
• HazardClass: 8
• PackingGroup: III
• Hazardous Substances Data: 25236-64-0(Hazardous Substances Data)

Usage

Chemical Properties

Clear colorless liquid

InChI:InChI=1/C12H11F3O4/c1-2-18-11(17)7-10(16)8-3-5-9(6-4-8)19-12(13,14)15/h3-6H,2,7H2,1H3

Upstream product

• 75-89-8 2,2,2-trifluoroethanol 
• 338741-98-3 C₁₃H₁₉NO₄S 
• 124-63-0 methanesulfonyl chloride 

Downstream Products

• 76588-84-6 4-Methoxy-3-(2,2,2-trifluoro-ethoxy)-benzaldehyde 
• 530-48-3 1,1-Diphenylethylene 
• 62149-35-3 1-(2,2,2-trifluoroethoxy)-4-nitrobenzene 
• 76579-46-9 4-(2,2,2-trifluoroethoxy)benzaldehyde 
• 62158-88-7 1-(2,2,2-trifluoroethoxy)-4-methoxybenzene 
• 19013-30-0 p-methoxyphenyl mesylate 
• 76579-44-7 1-(4-(2,2,2-trifluoroethoxy)phenyl)ethan-1-one 
• 103-50-4 dibenzyl ether 
• 67696-28-0 ((2,2,2-trifluoroethoxy)methyl)benzene 
• 160969-02-8 2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethanol 
• 1015485-45-6 tert-butyl 4-{5-chloro-4-methyl-2-[(methylsulfonyl)(2.2.2-trifluoroethyl)-amino]phenyl}piperidine-1-carboxylate 
• 1015485-73-0 tert-butyl 4-{5-chloro-2-[(cyclopropylsulfonyl)(2,2,2-trifluoroethyl)amino]-4-methylphenyl}piperidine-1-carboxylate 
• 330999-80-9 ethyl 4-(2,2,2-trifluoroethoxy)-3-methoxybenzoate 
• 17351-95-0 (2,2,2-trifluoroethoxy)benzene 

Relevant articles and documents

Chemical modification of poly(vinylacetylene) and synthesis of poly(1,2,3-triazole)s

A series of new polymers containing 1,2,3-triazoles were synthesized and their structures and properties were characterized by FT-IR, 1H NMR, TGA, DSC and GPC. The results showed that the polymers modified by alkyl groups had good solubility, thermal stability and reasonable molecular weights. It was also demonstrated that the properties of fluorine-containing polymers were seriously affected by fluorine atoms with hydrophobic and chemical proof properties.

Olefination with Sulfonyl Halides and Esters: Scope, Limitations, and Mechanistic Studies of the Hawkins Reaction

Carbanions of alkanesulfonyl halides and esters react with nonenolizable carbonyl compounds to give olefins. Mechanistic studies reveal that initial aldol-type addition of the carbanions is followed by cyclization-fragmentation to alkenes, and the leaving group on the sulfonyl moiety (RSO2X) controls carbanion stability and rate of the olefin formation.

ADRENERGIC RECEPTOR ANTAGONISTS

The present invention relates to α1a and/or α1b adrenergic receptor antagonists, which can be used to treat a disease or disorder mediated through α1a and/or α1b adrenergic receptors. Compounds and pharmaceutical compositions disclosed herein can be used to treat benign prostatic hyperplasia (BPH) and related symptoms thereof. Further, such compounds can be used to treat lower urinary tract symptoms that may or may not be associated with BPH. The present invention also relates to processes to prepare the disclosed compounds, pharmaceutical compositions thereof, and methods of treating BPH or related symptoms thereof.